佐丹奴(00709.HK)第二季銷售額按年增44%至逾8.1億元
佐丹奴國際(00709.HK)公佈,今年第二季集團銷售額反彈,按年增長44%至8.12億元,主因於2019新型冠狀病毒大流行爆發後,由於去年的低銷售基數,大部分地區的銷售額有所改善。
其中,亞太其他地區第二季銷售額爲2.48億元,按年增119.5%;中國大陸銷售額爲1.75億元,按年增18.2%;香港及澳門爲9,400萬元,增3.3%。
集團指,線上業務的增長勢頭從去年開始持續,今年第二季線上業務銷售額按年增長約12.5%至9,000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.